Another good example, unfortunately. Imetelstat does have a real role to play in LR-MDS (something like 80% of patients aren't really candidates for lenalidomide or luspatercept), so I expect their story to be ultimately successful, unlike, say...Clovis?
The ongoing research in MPN has those researchers pretty excited right now, too.